Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Satraplatin in Metastatic Prostate Cancer
NCT00499694Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Oct 2007
- Primary completion
- Nov 2012
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of satraplatin, bevacizumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Barbara Ann Karmanos Cancer Institute. Started Oct 2007; status: completed.
02
Drugs
satraplatinbevacizumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00499694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00499694.